GlassScriptPhysician profile
Sriramamurthy Ravipati
NPI 1730239732
$4,354.73
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $1,685 · 2021: $1,452 · 2022: $171.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,532.51 | 2019-2021 | |
| Alkermes, INC. | $788.72 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $729.19 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $520.96 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.47 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $120.33 | 2019-2021 | |
| Shire North American Group INC | $77.22 | 2019 | |
| Vertical Pharmaceuticals, LLC | $57.63 | 2019 | |
| Ironshore Pharmaceuticals INC. | $44.98 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $35.96 | 2019 | |
| Lundbeck LLC | $26.54 | 2019 | |
| Tris Pharma INC | $21.09 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.18 | 2021 | |
| Neurocrine Biosciences, INC. | $11.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sriramamurthy Ravipati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.